US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Exelixis

34.57

-2.1100-5.75%

Post-market: 34.50-0.0700-0.20%19:54 EDT

Volume:2.95M

Turnover:103.20M

Market Cap:9.68B

PE:19.64

High:36.45

Open:35.80

Low:34.48

Close:36.68

Loading ...

Overview Company News Filings

Exelixis (EXEL) Gets a Buy from RBC Capital

Biotech Stock Roundup: CORT Up on Study Data, Updates From AXSM, BMY, EXEL & More

Is Exelixis, Inc. (EXEL) The Most Profitable Biotech Stock To Buy Right Now?

Exelixis Launches Special Equity Award Program

Guggenheim Remains a Buy on Exelixis (EXEL)

FDA Expands Exelixis Cabometyx Label for Neuroendocrine Tumors

Truist Financial Reaffirms Their Buy Rating on Exelixis (EXEL)

Exelixis Price Target Maintained With a $40.00/Share by HC Wainwright & Co.

Exelixis to present positive preclinical data across pipeline portfolio at AACR

Exelixis Stock Rises 13.3% Year to Date: Buy, Sell or Hold?

BUZZ-U.S. STOCKS ON THE MOVE-SurgePays, B. Riley, CarMax

Exelixis Gains Buy Rating from Silvan Tuerkcan Following Early FDA Approval and Growth Potential in Neuroendocrine Tumor Market

Exelixis (NasdaqGS:EXEL) Celebrates FDA Approval For Expanded CABOMETYX® Use In Treating NET

Simply Wall St.

BUZZ-Exelixis' cancer drug gets FDA approval but analysts say its priced in; shares down

Exelixis Gets FDA Approval for Drug Treating Patients With Previously Treated Advanced Neuroendocrine Tumors

MT Newswires Live

Exelixis Gets Expanded FDA Approval of Cabometyx in Advanced Neuroendocrine Tumors

Here's Why Exelixis (EXEL) is a Strong Growth Stock

BRIEF-Exelixis Announces U.S. FDA Approval Of CABOMETYX® (cabozantinib) For Patients With Previously Treated Advanced Neuroendocrine Tumors

Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors

BRIEF-FDA Approves Cabozantinib For Adults And Pediatric Patients 12 Years Of Age And Older With pNET And epNET

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/EXEL/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"EXEL","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EXEL\",,,,,undefined,":{"symbol":"EXEL","market":"US","secType":"STK","nameCN":"Exelixis","latestPrice":34.57,"timestamp":1743796800000,"preClose":36.68,"halted":0,"volume":2945045,"hourTrading":{"tag":"盘后","latestPrice":34.5,"preClose":34.57,"latestTime":"19:54 EDT","volume":32702,"amount":1130525.8904,"timestamp":1743810842976},"delay":0,"floatShares":235894721,"shares":279881450,"eps":1.76,"marketStatus":"Market Closed","change":-2.11,"latestTime":"04-04 16:00:00 EDT","open":35.8,"high":36.45,"low":34.48,"amount":103196830.022485,"amplitude":0.053708,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.76,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1744012800000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":955425600000,"exchange":"NASDAQ","adjPreClose":36.68,"preHourTrading":{"tag":"盘前","latestPrice":35.82,"preClose":36.68,"latestTime":"09:29 EDT","volume":2569,"amount":91777.11909800001,"timestamp":1743773399999},"postHourTrading":{"tag":"盘后","latestPrice":34.5,"preClose":34.57,"latestTime":"19:54 EDT","volume":32702,"amount":1130525.8904,"timestamp":1743810842976},"volumeRatio":1.2943524288249675,"impliedVol":0.5431,"impliedVolPercentile":0.7092},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EXEL\",,,,,undefined,":{"symbol":"EXEL","floatShares":235894721,"roa":"14.64%","roe":"23.13%","lyrEps":1.797286,"volumeRatio":1.2943524288249675,"shares":279881450,"dividePrice":0,"high":36.45,"amplitude":0.053708,"preClose":36.68,"low":34.48,"week52Low":20.14,"pbRate":"4.31","psRate":"4.46","week52High":40.02,"institutionHeld":0.7772,"latestPrice":34.57,"eps":1.76,"divideRate":0,"volume":2945045,"delay":0,"ttmEps":1.76,"open":35.8,"prevYearClose":33.3,"prevWeekClose":36.7,"prevMonthClose":36.92,"prevQuarterClose":36.92,"fiveDayClose":36.7,"twentyDayClose":38.58,"sixtyDayClose":34.21},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"EXEL\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2525768147","title":"Exelixis (EXEL) Gets a Buy from RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2525768147","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525768147?lang=en_us&edition=fundamental","pubTime":"2025-04-05 09:48","pubTimestamp":1743817726,"startTime":"0","endTime":"0","summary":"RBC Capital analyst Gregory Renza maintained a Buy rating on Exelixis (EXEL – Research Report) on April 3 and set a price target of $40.00. The com...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/exelixis-exel-gets-a-buy-from-rbc-capital?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/exelixis-exel-gets-a-buy-from-rbc-capital?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","EXEL","BK4532","BK4207"],"gpt_icon":0},{"id":"2524449342","title":"Biotech Stock Roundup: CORT Up on Study Data, Updates From AXSM, BMY, EXEL & More","url":"https://stock-news.laohu8.com/highlight/detail?id=2524449342","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524449342?lang=en_us&edition=fundamental","pubTime":"2025-04-03 03:00","pubTimestamp":1743620400,"startTime":"0","endTime":"0","summary":"It was a busy week in the biotech sector, marked by significant regulatory and pipeline updates. Among these, shares of Corcept Therapeutics Incorporated CORT skyrocketed after a late-stage study met its primary goal. On the other hand, Axsome Therapeutics’ AXSM shares declined after announcing results from a study on major depressive disorder .Shares of Corcept Therapeutics Incorporated surged on March 31 after the company announced the success of the late-stage ROSELLA study.The phase III ROSELLA study evaluated its pipeline candidate, relacorilant, in combination with nab-paclitaxel for treating patients with platinum-resistant ovarian cancer.Axsome Therapeutics announced top-line data from the phase III PARADIGM study, which evaluated solriamfetol for the treatment of major depressive disorder  with and without severe excessive daytime sleepiness .Nonetheless, in the prespecified subgroup of patients with severe EDS, treatment with solriamfetol led to greater improvements in depres","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biotech-stock-roundup-cort-study-190000499.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1868836591.USD","BLUE","EXEL","BK4007","BK4532","LU1571399168.USD","LU2242652126.USD","LU0306807586.USD","LU1074936037.SGD","LU1670710661.SGD","LU0321505439.SGD","LU1670710588.SGD","LU2360032135.SGD","LU1093756168.USD","LU0985481810.HKD","LU0882574055.USD","BMY","LU1989771016.USD","AXSM","BK4534","IE00BJT1NW94.SGD","LU2125154778.USD","LU0096364046.USD","LU0566484027.USD","BK4578","BK4556","LU1868836757.USD","LU0225284248.USD","BK4505","PFS","LU1585245621.USD","LU2125154935.USD","OS","LU1291159041.SGD","BK4588","CORT","LU0306806265.USD","LU1323610961.USD","LU1093756325.SGD","LU1670711123.USD","BK4585","LU1670711040.USD","IE00BSNM7G36.USD","IE00BJJMRZ35.SGD","LU2242646821.SGD","LU0321505868.SGD","LU1718418525.SGD","IE00B2B36J28.USD","LU0456855351.SGD","BK4097"],"gpt_icon":1},{"id":"2524945144","title":"Is Exelixis, Inc. (EXEL) The Most Profitable Biotech Stock To Buy Right Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2524945144","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524945144?lang=en_us&edition=fundamental","pubTime":"2025-04-02 21:48","pubTimestamp":1743601682,"startTime":"0","endTime":"0","summary":"We recently published a list of 7 Most Profitable Biotech Stocks To Buy Right Now. In this article, we are going to take a look at where Exelixis, Inc.  stands against other most profitable biotech stocks to buy right now.With improved market conditions, innovative breakthroughs, and more investor interest, the biotechnology industry is gaining new traction. The sector has bounced back from a difficult 2024 and is set to grow significantly, thanks to developments in AI-driven drug discovery, personalized medicine, and the rising demand for biologics. The global biotech market was expected to grow by a robust 13%, from $483.0 billion in 2024 to $546.0 billion in 2025, according to MarketsandMarkets. The sector’s resilience and growth potential are demonstrated by this expansion.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exelixis-inc-exel-most-profitable-134802137.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NVIW.SI","USJW.SI","BK4139","SQQQ","QLD","BK4532","TSYW.SI","TQQQ","MNQmain","EXEL","PSQ","USAW.SI",".IXIC","QID","NQmain"],"gpt_icon":1},{"id":"2524777829","title":"Exelixis Launches Special Equity Award Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2524777829","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524777829?lang=en_us&edition=fundamental","pubTime":"2025-04-01 04:37","pubTimestamp":1743453431,"startTime":"0","endTime":"0","summary":"An announcement from Exelixis ( ($EXEL) ) is now available. On March 28, 2025, Exelixis, Inc.’s Board of Directors approved a Special Equity Award ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/exelixis-launches-special-equity-award-program?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/exelixis-launches-special-equity-award-program?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4215","BK4532","EXEL","BK4588","EQR","BK4585","BK4139"],"gpt_icon":0},{"id":"2523066076","title":"Guggenheim Remains a Buy on Exelixis (EXEL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2523066076","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523066076?lang=en_us&edition=fundamental","pubTime":"2025-03-30 22:05","pubTimestamp":1743343514,"startTime":"0","endTime":"0","summary":"Guggenheim analyst Michael Schmidt maintained a Buy rating on Exelixis (EXEL – Research Report) on March 26 and set a price target of $42.00. The c...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/guggenheim-remains-a-buy-on-exelixis-exel?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/guggenheim-remains-a-buy-on-exelixis-exel?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EXEL","BK4139","BK4532"],"gpt_icon":0},{"id":"2522537272","title":"FDA Expands Exelixis Cabometyx Label for Neuroendocrine Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2522537272","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522537272?lang=en_us&edition=fundamental","pubTime":"2025-03-28 03:00","pubTimestamp":1743102000,"startTime":"0","endTime":"0","summary":"Exelixis, Inc. EXEL announced that the FDA has approved the label expansion of its lead drug Cabometyx .The regulatory body approved Cabometyx for the treatment of adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors .Simultaneously, the drug was approved for adult and pediatric patients  with previously treated, unresectable, locally advanced or metastatic, well-differentiated extra-pancreatic NET .Consequently, Cabometyx is now the first and only systemic treatment that is FDA-approved for previously treated neuroendocrine tumors regardless of primary tumor site, grade, somatostatin receptor expression and functional status.The approval came ahead of the target action date of April 3, 2025.The company is now focused on developing zanzalintinib, a next-generation oral TKI. In January 2025, results from an expansion cohort of the phase Ib/II STELLAR-001 study ev","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fda-expands-exelixis-cabometyx-label-190000158.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1670710661.SGD","IE00BFTCPJ56.SGD","RCC","LU1670710588.SGD","LU1989771016.USD","LU1032466523.USD","LU2242646821.SGD","LU1585245621.USD","LU0321505868.SGD","CRC","LU0456855351.SGD","EXEL","LU1261432733.SGD","IE00BKVL7J92.USD","LU1868837300.USD","LU2360032135.SGD","LU1868836757.USD","LU0225284248.USD","IE00BZ1G4Q59.USD","LU1868836914.USD","LU1093756325.SGD","BMY","IE0002141913.USD","LU0096364046.USD","DTC","IE00BFXG1179.USD","LU0237698245.USD","LU1718418525.SGD","LU0321505439.SGD","LU0456854461.SGD","LU1323610961.USD","LU0882574055.USD","BK4588","IE0009355771.USD","LU0154236417.USD","BK4139","BK4534","LU2133065610.SGD","LU0985481810.HKD","IE00B2B36J28.USD","LU0306806265.USD","BAYRY","IE00BSNM7G36.USD","LU1074936037.SGD","LU1093756168.USD","LU0266512127.USD","LU2125154935.USD","BK4559"],"gpt_icon":1},{"id":"2522371147","title":"Truist Financial Reaffirms Their Buy Rating on Exelixis (EXEL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2522371147","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522371147?lang=en_us&edition=fundamental","pubTime":"2025-03-27 19:38","pubTimestamp":1743075495,"startTime":"0","endTime":"0","summary":"In a report released today, Asthika Goonewardene from Truist Financial maintained a Buy rating on Exelixis (EXEL – Research Report). The company’s ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/truist-financial-reaffirms-their-buy-rating-on-exelixis-exel-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/truist-financial-reaffirms-their-buy-rating-on-exelixis-exel-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EXEL"],"gpt_icon":0},{"id":"2522375336","title":"Exelixis Price Target Maintained With a $40.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2522375336","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522375336?lang=en_us&edition=fundamental","pubTime":"2025-03-27 18:57","pubTimestamp":1743073020,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/EXEL/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 27, 2025 06:57 ET (10:57 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EXEL"],"gpt_icon":0},{"id":"2522966354","title":"Exelixis to present positive preclinical data across pipeline portfolio at AACR","url":"https://stock-news.laohu8.com/highlight/detail?id=2522966354","media":"TipRanks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522966354?lang=en_us&edition=fundamental","pubTime":"2025-03-27 05:20","pubTimestamp":1743024023,"startTime":"0","endTime":"0","summary":"The company states: “Exelixis  announced that preclinical data will be presented for four pipeline molecules at the American Association for Cancer Research Annual Meeting 2025 taking place April 25-30 in Chicago, IL. Exelixis will present preclinical data for XL495 and XL309, small molecules that have demonstrated synthetic lethality in the context of certain genetic anomalies frequently found in some tumors. Preclinical data will also be presented for the PD-L1xNKG2A-targeting bispecific antibody XB628 and the tissue factor-targeting antibody-drug conjugate XB371. Initial details about the poster presentations can be found below. Full data will be presented at the AACR Annual Meeting.” “We are excited to share preclinical data from four of our pipeline molecules that constitute the next phase in our commitment to the discovery and development of innovative cancer treatments,” said Dana T. Aftab, Ph.D., Executive Vice President, Discovery & Translational Research, and Chief Scientific","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/exelixis-present-positive-preclinical-data-212023385.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exelixis-present-positive-preclinical-data-212023385.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Exelixis to present positive preclinical data across pipeline portfolio at AACR","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","EXEL","BK4532"],"gpt_icon":0},{"id":"2522935496","title":"Exelixis Stock Rises 13.3% Year to Date: Buy, Sell or Hold?","url":"https://stock-news.laohu8.com/highlight/detail?id=2522935496","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522935496?lang=en_us&edition=fundamental","pubTime":"2025-03-27 03:00","pubTimestamp":1743015600,"startTime":"0","endTime":"0","summary":"Shares of Exelixis, Inc. EXEL have risen 13.3% year to date compared with the industry’s growth of 6.6%. The stock has also outperformed the sector and the S&P 500 Index in this timeframe.The company's upbeat performance can be attributed to its strong quarterly results, raised guidance and efforts to increase shareholders' returns.Last month, Exelixis announced a new share repurchase program of $500 million. Shares rallied following the announcement. Earlier, the company reported better-than-expected fourth-quarter results, which also drove the stock higher.Let’s delve deeper and analyze the company’s strengths and weaknesses to understand how to play the stock in such a scenario.Exelixis’ lead drug Cabometyx maintains its status as the leading tyrosine kinase inhibitor  for the treatment of renal cell carcinoma  in both the frontline immuno-oncology  +TKI market and the second-line monotherapy segment.Meanwhile, Exelixis collaborated with pharma giant Merck MRK to evaluate zanzalinti","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exelixis-stock-rises-13-3-190000591.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4516","LU0061475181.USD","LU1430594728.SGD","SG9999015358.SGD","LU1941712264.USD","IE00BFTCPJ56.SGD","RCC","SG9999015341.SGD","LU1868836591.USD","LU1989771016.USD","MRK","LU1868836914.USD","LU2242646821.SGD","LU1934455277.USD","LU1989772840.SGD","LU1934455194.USD","IE00BJT1NW94.SGD","SGXZ57979304.SGD","LU1929549753.HKD","CRC","BK4585","LU1699723380.USD","LU1989772923.USD","BK4588","LU1868837300.USD","LU1868837136.USD","IE00BFXG1179.USD","LU0306806265.USD","EXEL","BMY","LU1057294990.SGD","LU0266512127.USD","LU1670710588.SGD","LU1718418525.SGD","LU2133065610.SGD","LU2023250504.SGD","LU1037948897.HKD","LU1670710661.SGD","BK4581","LU0289739699.SGD","LU1093756325.SGD","LU1974910355.USD","LU1037948541.HKD","BK4550","SG9999014567.USD","LU0306807586.USD","SG9999014542.SGD","LU1323610961.USD","LU1670711123.USD","BK4559"],"gpt_icon":0},{"id":"2522335502","title":"BUZZ-U.S. STOCKS ON THE MOVE-SurgePays, B. Riley, CarMax","url":"https://stock-news.laohu8.com/highlight/detail?id=2522335502","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522335502?lang=en_us&edition=fundamental","pubTime":"2025-03-27 01:40","pubTimestamp":1743010809,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-SurgePays,B. Riley, CarMaxEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: https:/","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250326:nL6N3Q90QT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HUMA","LU0203345920.USD","PVLA","SG9999002232.USD","PSX","SARO","KMX","VRT","LU0823414551.USD","LU0054578231.USD","ALNY","LU0256863811.USD","AEP","IE00B29SXK94.USD","LU0075056555.USD","LU0654597011.USD","SCCO","WING","SURG","CTAS","LU1582987597.SGD","DLTR","COCO","CVX","LU2506952170.USD","IE00B894F039.SGD","LU0980610538.SGD","VVX","BK4563","WVE","BK4127","LU0050427557.USD","EXEL","FCX","LU1023059063.AUD","GWRS","XOM","BBIO","CHWY","JKS","EOG","LU2294711713.HKD","LU0266512127.USD","BK4547","ULTA","RILY","COTY"],"gpt_icon":1},{"id":"2522335625","title":"Exelixis Gains Buy Rating from Silvan Tuerkcan Following Early FDA Approval and Growth Potential in Neuroendocrine Tumor Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2522335625","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522335625?lang=en_us&edition=fundamental","pubTime":"2025-03-27 01:25","pubTimestamp":1743009920,"startTime":"0","endTime":"0","summary":"Exelixis (EXEL – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Silvan Tuerkcan from JMP Se...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/exelixis-gains-buy-rating-from-silvan-tuerkcan-following-early-fda-approval-and-growth-potential-in-neuroendocrine-tumor-market?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/exelixis-gains-buy-rating-from-silvan-tuerkcan-following-early-fda-approval-and-growth-potential-in-neuroendocrine-tumor-market?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EXEL"],"gpt_icon":0},{"id":"2522939335","title":"Exelixis (NasdaqGS:EXEL) Celebrates FDA Approval For Expanded CABOMETYX® Use In Treating NET","url":"https://stock-news.laohu8.com/highlight/detail?id=2522939335","media":"Simply Wall St.","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522939335?lang=en_us&edition=fundamental","pubTime":"2025-03-27 01:22","pubTimestamp":1743009724,"startTime":"0","endTime":"0","summary":"Exelixis saw an 11% share price increase over the last quarter, a period marked by significant achievements including the FDA's approval of CABOMETYX for treating a broader range of pancreatic and extra-pancreatic neuroendocrine tumors. This regulatory milestone adds to its existing portfolio, potentially enhancing market confidence. During the same period, the company reported robust earnings growth and initiated a $500 million share repurchase program, reflecting a strong financial position. Despite broader market volatility and declines in the tech sector, Exelixis's positive developments helped it outperform general market trends.View our complete analysis and fair value estimate and you decide.NasdaqGS:EXEL Earnings Per Share Growth as at Mar 2025","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exelixis-nasdaqgs-exel-celebrates-fda-172204854.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4548","BK4532","NET","BK4116","BK4607","BK4554","EXEL","BK4588","BK4139","LU2286300806.USD","BK4560","BK4613","BK4585"],"gpt_icon":0},{"id":"2522387194","title":"BUZZ-Exelixis' cancer drug gets FDA approval but analysts say its priced in; shares down","url":"https://stock-news.laohu8.com/highlight/detail?id=2522387194","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522387194?lang=en_us&edition=fundamental","pubTime":"2025-03-27 00:30","pubTimestamp":1743006641,"startTime":"0","endTime":"0","summary":"BUZZ-Exelixis' cancer drug gets FDA approval but analysts say its priced in; shares down** Shares of cancer drugmaker Exelixis EXEL.O fall 2.3% to $36.83** US FDA approved EXEL's cancer drug, Cabometyx, for treating adult and pediatric patients with previously treated advanced neuroendocrine tumors ** Citizens Bank analyst Silvan Tuerkcan notes EXEL's shares declined as investors had already factored the approval into the stock price** Tuerkcan says investor focus will now be on the launch of the drug for patients with NET, and size of the opportunity, which is expected to drive \"a significant portion\" of the company's sales growth in the near term** Leerink Partners analyst Andrew Berens estimates Cabometyx to bring in $75 million for NET in 2025, with peak sales reaching $750 million before losing exclusivity impact starting in 2030** Stock gained ~59% in the last 12 months  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250326:nL3N3Q91CB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EXEL","BK4139","BK4532"],"gpt_icon":0},{"id":"2522802127","title":"Exelixis Gets FDA Approval for Drug Treating Patients With Previously Treated Advanced Neuroendocrine Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2522802127","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522802127?lang=en_us&edition=fundamental","pubTime":"2025-03-26 21:59","pubTimestamp":1742997545,"startTime":"0","endTime":"0","summary":"Exelixis  said Wednesday it received approval for Cabometyx for patients with previously treated advanced neuroendocrine tumors from the US Food and Drug Administration.The approval was for the treatment of patients 12 years of age and older with previously treated, unresectable, pancreatic neuroendocrine tumors and extra-pancreatic neuroendocrine tumors.The company said the approval was based on a phase 3 trial that showed a statistically significant and clinically meaningful improvement in progression-free survival in patients with the treatment compared with those with a placebo.Price: 37.41, Change: -0.30, Percent Change: -0.81","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00B19Z4B17.USD","BK6088","BK4532","IE0031619046.USD","BLZ.SI","IE00B7SZL793.SGD","BK6522","EXEL","BK4139","IE00B66KJ199.SGD","BK4157","AEIS"],"gpt_icon":0},{"id":"2522804953","title":"Exelixis Gets Expanded FDA Approval of Cabometyx in Advanced Neuroendocrine Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2522804953","media":"Dow Jones","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522804953?lang=en_us&edition=fundamental","pubTime":"2025-03-26 21:46","pubTimestamp":1742996760,"startTime":"0","endTime":"0","summary":"Exelixis has won U.S. Food and Drug Administration expanded  approval of its Cabometyx cancer drug for certain patients with advanced neuroendocrine tumors.Exelixis on Wednesday said the approval covers Cabometyx for patients 12 and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic and extra-pancreatic neuroendocrine tumors.The Alameda, Calif., oncology company said the green light makes Cabometyx the first and only systemic treatment that is FDA-approved for previously treated neuroendocrine tumors regardless of primary tumor site, grade, somatostatin receptor expression and functional status.Neuroendocrine tumors are heterogeneous tumors that arise from the neuroendocrine cells of the digestive tract and other organs, such as the lung and pancreas, and most patients with advanced disease face a poor prognosis, Exelixis said.The company's cabozantinib franchise, anchored by Cabometyx, generated $1.81 billion in U.S. net product","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4157","BK6522","AEIS","BK6088","IE00B7SZL793.SGD","EXEL","BK4139","IE0031619046.USD","IE00B66KJ199.SGD","IE00B19Z4B17.USD","BLZ.SI","BK4532"],"gpt_icon":0},{"id":"2522382512","title":"Here's Why Exelixis (EXEL) is a Strong Growth Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2522382512","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522382512?lang=en_us&edition=fundamental","pubTime":"2025-03-26 21:45","pubTimestamp":1742996708,"startTime":"0","endTime":"0","summary":"Taking full advantage of the stock market and investing with confidence are common goals for new and old investors alike.Achieving those goals is made easier with the Zacks Style Scores, a unique set of guidelines that rates stocks based on popular investing methodologies, namely value, growth, and momentum. The Style Scores can help you narrow down which stocks are better for your portfolio and which ones can beat the market over the long-term.Why This 1 Growth Stock Should Be On Your Watchlist. Different than value or momentum investors, growth-oriented investors are concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, they'll want to focus on the Growth Style Score, which analyzes characteristics like projected and historical earnings, sales, and cash flow to find stocks that will see sustainable growth over time.Seven analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has inc","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/heres-why-exelixis-exel-strong-134508754.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4532","EXEL","BK4139"],"gpt_icon":0},{"id":"2522809990","title":"BRIEF-Exelixis Announces U.S. FDA Approval Of CABOMETYX® (cabozantinib) For Patients With Previously Treated Advanced Neuroendocrine Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2522809990","media":"Reuters","labels":["productRelease","policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522809990?lang=en_us&edition=fundamental","pubTime":"2025-03-26 21:28","pubTimestamp":1742995712,"startTime":"0","endTime":"0","summary":"BRIEF-Exelixis Announces U.S. FDA Approval Of CABOMETYX (cabozantinib) For Patients With Previously Treated Advanced Neuroendocrine TumorsMarch 26 (Reuters) - Exelixis Inc EXEL.O:EXELIXIS ANNOUNCES U.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250326:nFWN3Q915X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EXEL","BK4532","BK4139"],"gpt_icon":0},{"id":"2522615804","title":"Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2522615804","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522615804?lang=en_us&edition=fundamental","pubTime":"2025-03-26 21:15","pubTimestamp":1742994900,"startTime":"0","endTime":"0","summary":"– FDA approval based on the phase 3 CABINET pivotal trial, which demonstrated a statistically significant and clinically meaningful improvement in progression-free survival versus placebo –。– CABOMETYX is now the first and only systemic treatment that is FDA approved for previously treated neuroendocrine tumors regardless of primary tumor site, grade, somatostatin receptor expression and functional status –。– Exelixis is prepared to immediately support these new indications –。ALAMEDA, Calif., March 26, 2025----Exelixis, Inc.  today announced that the U.S. Food and Drug Administration  has approved CABOMETYX  for the treatment of 1) adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors ; and 2) adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated extra-pancreatic NET . NET","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exelixis-announces-u-fda-approval-131500269.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4006","BK4585","HCC","IE00B19Z4B17.USD","NCI","BK4548","BK4613","DTC","AEIS","NET","BK4532","IE0031619046.USD","LU2286300806.USD","BK4139","IE00B66KJ199.SGD","BK4157","BK4202","IE00B7SZL793.SGD","BK4116","BK4588","BK4554","BK4190","BK4607","RCC","BK4560","EXEL"],"gpt_icon":0},{"id":"2522387010","title":"BRIEF-FDA Approves Cabozantinib For Adults And Pediatric Patients 12 Years Of Age And Older With pNET And epNET","url":"https://stock-news.laohu8.com/highlight/detail?id=2522387010","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522387010?lang=en_us&edition=fundamental","pubTime":"2025-03-26 20:37","pubTimestamp":1742992644,"startTime":"0","endTime":"0","summary":"BRIEF-FDA Approves Cabozantinib For Adults And Pediatric Patients 12 Years Of Age And Older With pNET And epNETMarch 26  - Exelixis Inc EXEL.O:FDA APPROVES CABOZANTINIB FOR ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH PNET AND EPNETFurther company coverage: EXEL.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250326:nFWN3Q90M0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EXEL","BK4139","BK4532"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":200}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/EXEL\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-02-11","symbol":"EXEL","fiscalQuarterEnding":"2024/12","expectedEps":0.45,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1739250000000,"reportTimeType":"post","actualEps":0.48},{"market":"US","date":"2025-01-12","symbol":"EXEL","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1736658000000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-10-29","symbol":"EXEL","fiscalQuarterEnding":"2024/09","expectedEps":0.36,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1730174400000,"reportTimeType":"post","actualEps":0.4},{"market":"US","date":"2024-08-06","symbol":"EXEL","fiscalQuarterEnding":"2024/06","expectedEps":0.31,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1722916800000,"reportTimeType":"post","actualEps":0.75},{"market":"US","date":"2024-04-30","symbol":"EXEL","fiscalQuarterEnding":"2024/03","expectedEps":0.22,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1714449600000,"reportTimeType":"post","actualEps":0.12}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"EXEL\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"EXEL\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.1905,"buy":0.3333,"hold":0.4286,"sell":0.0476,"strongSell":0,"meanLabel":"BUY","meanPercent":0.3333,"analysts":21,"updateTime":1740456000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/EXEL\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"EXEL","date":"2025-04-04","current":19.694421,"percent":0.104355,"low":16.158427,"twenty":21.399258,"median":31.337682,"eighty":58.191612,"high":123.671097,"avg":38.332101,"sd":22.122729,"marketCap":10266051586},"quantilePoints":[{"date":"2020-04-09","current":17.162342,"twenty":-27.322645,"median":-2.70229,"eighty":15.716223,"marketCap":5509317597},{"date":"2020-04-17","current":18.514757,"twenty":-27.325861,"median":-2.695768,"eighty":15.913527,"marketCap":5943459162},{"date":"2020-04-24","current":25.26731,"twenty":-27.325861,"median":-2.675639,"eighty":15.998656,"marketCap":8111109648},{"date":"2020-05-01","current":22.952965,"twenty":-27.325861,"median":-2.655085,"eighty":16.258055,"marketCap":7368177253},{"date":"2020-05-08","current":27.133421,"twenty":-27.325861,"median":-2.655085,"eighty":16.384068,"marketCap":7973128644},{"date":"2020-05-15","current":26.882959,"twenty":-27.325861,"median":-2.655085,"eighty":16.477819,"marketCap":7899530533},{"date":"2020-05-22","current":25.693263,"twenty":-27.325861,"median":-2.655085,"eighty":16.669769,"marketCap":7549939508},{"date":"2020-05-29","current":25.787186,"twenty":-27.325861,"median":-2.655085,"eighty":16.772736,"marketCap":7577538799},{"date":"2020-06-05","current":23.345178,"twenty":-27.325861,"median":-2.655085,"eighty":16.914711,"marketCap":6859957221},{"date":"2020-06-12","current":23.36605,"twenty":-27.325861,"median":-2.655085,"eighty":17.072198,"marketCap":6866090397},{"date":"2020-06-19","current":25.234082,"twenty":-27.325861,"median":-2.655085,"eighty":17.193665,"marketCap":7415009638},{"date":"2020-06-26","current":23.877411,"twenty":-27.325861,"median":-2.498063,"eighty":17.327033,"marketCap":7016353206},{"date":"2020-07-02","current":24.503566,"twenty":-27.325861,"median":2.570279,"eighty":17.449214,"marketCap":7200348483},{"date":"2020-07-10","current":26.027212,"twenty":-27.325861,"median":7.700066,"eighty":17.686188,"marketCap":7648070322},{"date":"2020-07-17","current":25.672391,"twenty":-27.325861,"median":7.798866,"eighty":17.752451,"marketCap":7543806332},{"date":"2020-07-24","current":25.661955,"twenty":-27.325861,"median":7.918086,"eighty":17.906096,"marketCap":7540739744},{"date":"2020-07-31","current":24.096565,"twenty":-27.325861,"median":7.952297,"eighty":18.137028,"marketCap":7080751553},{"date":"2020-08-07","current":24.532882,"twenty":-27.325861,"median":8.048191,"eighty":18.372123,"marketCap":6909146512},{"date":"2020-08-14","current":24.115955,"twenty":-27.325861,"median":8.142361,"eighty":18.523046,"marketCap":6791728101},{"date":"2020-08-21","current":24.412193,"twenty":-27.325861,"median":8.236764,"eighty":18.814893,"marketCap":6875156972},{"date":"2020-08-28","current":23.731943,"twenty":-27.325861,"median":8.306231,"eighty":18.921262,"marketCap":6683579564},{"date":"2020-09-04","current":22.678653,"twenty":-27.325861,"median":8.452997,"eighty":19.15433,"marketCap":6386943578},{"date":"2020-09-11","current":23.84166,"twenty":-27.325861,"median":8.522074,"eighty":19.393808,"marketCap":6714479146},{"date":"2020-09-18","current":29.404349,"twenty":-27.325861,"median":8.639223,"eighty":21.878582,"marketCap":8281087949},{"date":"2020-09-25","current":26.156704,"twenty":-27.325861,"median":8.733376,"eighty":22.567702,"marketCap":7366460324},{"date":"2020-10-02","current":25.673946,"twenty":-27.325861,"median":8.760246,"eighty":22.741605,"marketCap":7230502164},{"date":"2020-10-09","current":26.233507,"twenty":-27.325861,"median":8.79746,"eighty":22.926619,"marketCap":7388090032},{"date":"2020-10-16","current":25.487426,"twenty":-27.325861,"median":8.876649,"eighty":23.321013,"marketCap":7177972875},{"date":"2020-10-23","current":24.45608,"twenty":-27.325861,"median":8.972487,"eighty":23.456447,"marketCap":6887516805},{"date":"2020-10-30","current":22.470189,"twenty":-27.325861,"median":8.98742,"eighty":23.487127,"marketCap":6328234373},{"date":"2020-11-06","current":42.232952,"twenty":-27.325861,"median":9.087264,"eighty":23.557982,"marketCap":6425152432},{"date":"2020-11-13","current":41.111363,"twenty":-27.325861,"median":9.098481,"eighty":23.685842,"marketCap":6254518253},{"date":"2020-11-20","current":38.562295,"twenty":-27.325861,"median":9.113834,"eighty":23.779449,"marketCap":5866713302},{"date":"2020-11-27","current":39.581922,"twenty":-27.325861,"median":9.129175,"eighty":23.84411,"marketCap":6021835283},{"date":"2020-12-04","current":38.705043,"twenty":-27.325861,"median":9.164612,"eighty":23.920269,"marketCap":5888430379},{"date":"2020-12-11","current":40.519979,"twenty":-27.325861,"median":9.190147,"eighty":24.042286,"marketCap":6164547505},{"date":"2020-12-18","current":40.683119,"twenty":-27.325861,"median":9.209534,"eighty":24.112523,"marketCap":6189367021},{"date":"2020-12-24","current":42.232952,"twenty":-27.325861,"median":9.239511,"eighty":24.160872,"marketCap":6425152432},{"date":"2020-12-31","current":40.92783,"twenty":-27.325861,"median":9.247119,"eighty":24.259288,"marketCap":6226596297},{"date":"2021-01-08","current":46.535778,"twenty":-27.325861,"median":9.290936,"eighty":24.393046,"marketCap":7079767190},{"date":"2021-01-15","current":48.381303,"twenty":-27.325861,"median":9.331472,"eighty":24.439962,"marketCap":7360537974},{"date":"2021-01-22","current":45.149086,"twenty":-27.325861,"median":9.352389,"eighty":24.47852,"marketCap":6868801296},{"date":"2021-01-29","current":45.291833,"twenty":-27.325861,"median":9.385679,"eighty":24.575729,"marketCap":6890518373},{"date":"2021-02-05","current":47.249517,"twenty":-27.325861,"median":9.422035,"eighty":24.692782,"marketCap":7188352576},{"date":"2021-02-12","current":61.152553,"twenty":-27.325861,"median":9.475859,"eighty":24.765611,"marketCap":6835693472},{"date":"2021-02-19","current":61.989876,"twenty":-27.325861,"median":9.52696,"eighty":24.818203,"marketCap":6929290370},{"date":"2021-02-26","current":60.454783,"twenty":-27.325861,"median":9.582451,"eighty":24.859848,"marketCap":6757696057},{"date":"2021-03-05","current":62.324806,"twenty":-27.329077,"median":9.628878,"eighty":24.949115,"marketCap":6966729130},{"date":"2021-03-12","current":64.976331,"twenty":-27.329077,"median":9.656734,"eighty":25.006772,"marketCap":7263119308},{"date":"2021-03-19","current":65.311261,"twenty":-27.329077,"median":9.710451,"eighty":25.161223,"marketCap":7300558067},{"date":"2021-03-26","current":63.329595,"twenty":-27.325861,"median":9.736947,"eighty":25.234082,"marketCap":7079045408},{"date":"2021-04-01","current":64.529759,"twenty":-27.325861,"median":9.747742,"eighty":25.270502,"marketCap":7213200962},{"date":"2021-04-09","current":64.529759,"twenty":-27.329077,"median":9.805299,"eighty":25.357929,"marketCap":7213200962},{"date":"2021-04-16","current":66.075436,"twenty":-27.329077,"median":9.834498,"eighty":25.412148,"marketCap":7385978281},{"date":"2021-04-23","current":69.268568,"twenty":-27.329077,"median":9.92067,"eighty":25.491815,"marketCap":7742909830},{"date":"2021-04-30","current":68.960459,"twenty":-27.329077,"median":9.944579,"eighty":25.677015,"marketCap":7708469067},{"date":"2021-05-07","current":121.493789,"twenty":-27.329077,"median":9.977077,"eighty":25.790166,"marketCap":7869152717},{"date":"2021-05-14","current":123.671097,"twenty":-27.329077,"median":10.042797,"eighty":25.900353,"marketCap":8010176959},{"date":"2021-05-21","current":118.348789,"twenty":-27.329077,"median":10.090291,"eighty":26.029567,"marketCap":7665451034},{"date":"2021-05-28","current":109.107325,"twenty":-27.329077,"median":10.142137,"eighty":26.116578,"marketCap":7066881472},{"date":"2021-06-04","current":108.236402,"twenty":-27.329077,"median":10.259913,"eighty":26.305665,"marketCap":7010471775},{"date":"2021-06-11","current":111.187864,"twenty":-27.329077,"median":10.30588,"eighty":26.528137,"marketCap":7201637970},{"date":"2021-06-18","current":108.429941,"twenty":-27.329077,"median":10.499122,"eighty":26.899667,"marketCap":7023007264},{"date":"2021-06-25","current":113.316788,"twenty":-27.329077,"median":10.577409,"eighty":27.427848,"marketCap":7339528341},{"date":"2021-07-02","current":88.350322,"twenty":-27.329077,"median":10.668743,"eighty":28.437015,"marketCap":5722450363},{"date":"2021-07-09","current":87.140707,"twenty":-27.329077,"median":10.768777,"eighty":32.735526,"marketCap":5644103562},{"date":"2021-07-16","current":81.286167,"twenty":-27.329077,"median":12.586346,"eighty":38.333898,"marketCap":5264905044},{"date":"2021-07-23","current":80.947475,"twenty":-27.329077,"median":13.259462,"eighty":38.843712,"marketCap":5242967939},{"date":"2021-07-30","current":81.52809,"twenty":-27.329077,"median":13.665176,"eighty":39.250255,"marketCap":5280574404},{"date":"2021-08-06","current":57.789598,"twenty":-27.329077,"median":14.041856,"eighty":39.491398,"marketCap":5434591593},{"date":"2021-08-13","current":61.240223,"twenty":-27.329077,"median":14.246084,"eighty":40.05544,"marketCap":5759091844},{"date":"2021-08-20","current":61.776243,"twenty":-27.329077,"median":14.431907,"eighty":40.44398,"marketCap":5809499650},{"date":"2021-08-27","current":65.092863,"twenty":-27.329077,"median":14.633356,"eighty":40.76874,"marketCap":6121397950},{"date":"2021-09-03","current":66.231905,"twenty":-27.329077,"median":14.930088,"eighty":41.024831,"marketCap":6228514538},{"date":"2021-09-10","current":66.868428,"twenty":-27.329077,"median":15.002715,"eighty":41.184268,"marketCap":6288373808},{"date":"2021-09-17","current":69.41452,"twenty":-27.329077,"median":15.270884,"eighty":41.645802,"marketCap":6527810887},{"date":"2021-09-24","current":68.174975,"twenty":-27.329077,"median":15.454005,"eighty":42.220717,"marketCap":6411242835},{"date":"2021-10-01","current":72.16162,"twenty":-27.329077,"median":15.627908,"eighty":42.663031,"marketCap":6786150893},{"date":"2021-10-08","current":72.42963,"twenty":-27.329077,"median":15.773963,"eighty":43.366777,"marketCap":6811354796},{"date":"2021-10-15","current":73.099654,"twenty":-27.329077,"median":15.952475,"eighty":44.822559,"marketCap":6874364554},{"date":"2021-10-22","current":71.692603,"twenty":-27.329077,"median":16.00116,"eighty":45.312226,"marketCap":6742044063},{"date":"2021-10-29","current":72.061116,"twenty":-27.329077,"median":16.265432,"eighty":45.826118,"marketCap":6776699429},{"date":"2021-11-05","current":37.285528,"twenty":-27.329077,"median":16.391679,"eighty":45.919924,"marketCap":6125452889},{"date":"2021-11-12","current":34.858887,"twenty":-27.329077,"median":16.479897,"eighty":45.919924,"marketCap":5726792216},{"date":"2021-11-19","current":34.724073,"twenty":-27.329077,"median":16.682751,"eighty":45.919924,"marketCap":5704644400},{"date":"2021-11-26","current":32.855945,"twenty":-27.200425,"median":16.81027,"eighty":45.919924,"marketCap":5397738961},{"date":"2021-12-03","current":30.506341,"twenty":-26.943119,"median":16.933764,"eighty":45.919924,"marketCap":5011734182},{"date":"2021-12-10","current":32.066324,"twenty":-26.245177,"median":17.104522,"eighty":45.919924,"marketCap":5268016044},{"date":"2021-12-17","current":35.051477,"twenty":-24.694911,"median":17.218287,"eighty":45.919924,"marketCap":5758431952},{"date":"2021-12-23","current":37.131455,"twenty":-24.254275,"median":17.32582,"eighty":45.919924,"marketCap":6100141100},{"date":"2021-12-31","current":35.20555,"twenty":7.517288,"median":17.464132,"eighty":45.919924,"marketCap":5783743740},{"date":"2022-01-07","current":36.091466,"twenty":7.709485,"median":17.687208,"eighty":45.891374,"marketCap":5929286526},{"date":"2022-01-14","current":34.897405,"twenty":7.799575,"median":17.756166,"eighty":45.891374,"marketCap":5733120163},{"date":"2022-01-21","current":33.356681,"twenty":7.907699,"median":17.862859,"eighty":45.891374,"marketCap":5480002275},{"date":"2022-01-28","current":34.223338,"twenty":7.943549,"median":18.081923,"eighty":45.891374,"marketCap":5622381087},{"date":"2022-02-04","current":36.187761,"twenty":8.039903,"median":18.360975,"eighty":45.891374,"marketCap":5945106394},{"date":"2022-02-11","current":36.110725,"twenty":8.136529,"median":18.515656,"eighty":45.891374,"marketCap":5932450500},{"date":"2022-02-18","current":27.042003,"twenty":8.217909,"median":18.789229,"eighty":45.891374,"marketCap":6248406283},{"date":"2022-02-25","current":27.899162,"twenty":8.270506,"median":18.897922,"eighty":45.891374,"marketCap":6446464151},{"date":"2022-03-04","current":28.61807,"twenty":8.371042,"median":19.106053,"eighty":45.891374,"marketCap":6612577201},{"date":"2022-03-11","current":29.019,"twenty":8.507031,"median":19.335948,"eighty":45.891374,"marketCap":6705217172},{"date":"2022-03-18","current":29.572006,"twenty":8.621808,"median":21.199768,"eighty":45.891374,"marketCap":6832996441},{"date":"2022-03-25","current":30.249439,"twenty":8.73225,"median":22.506564,"eighty":45.891374,"marketCap":6989526047},{"date":"2022-04-01","current":31.645779,"twenty":8.756029,"median":22.697854,"eighty":45.891374,"marketCap":7312168702},{"date":"2022-04-08","current":31.825506,"twenty":8.792498,"median":22.852188,"eighty":45.891374,"marketCap":7353696965},{"date":"2022-04-14","current":31.995647,"twenty":8.865935,"median":22.952956,"eighty":45.891374,"marketCap":7393010230},{"date":"2022-04-22","current":31.067233,"twenty":8.939729,"median":23.213643,"eighty":45.891374,"marketCap":7178488062},{"date":"2022-04-29","current":30.956378,"twenty":8.974263,"median":23.420305,"eighty":45.891374,"marketCap":7152873475},{"date":"2022-05-06","current":29.778539,"twenty":9.039592,"median":23.531551,"eighty":45.891374,"marketCap":6880718486},{"date":"2022-05-13","current":21.60979,"twenty":9.09473,"median":23.549925,"eighty":45.891374,"marketCap":6440473677},{"date":"2022-05-20","current":19.113041,"twenty":9.107191,"median":23.549925,"eighty":45.891374,"marketCap":5696355204},{"date":"2022-05-27","current":19.801799,"twenty":9.125872,"median":23.549925,"eighty":45.891374,"marketCap":5901629266},{"date":"2022-06-03","current":20.490558,"twenty":9.145972,"median":23.549925,"eighty":45.891374,"marketCap":6106903327},{"date":"2022-06-10","current":19.521991,"twenty":9.183299,"median":23.549925,"eighty":45.891374,"marketCap":5818236678},{"date":"2022-06-17","current":19.973989,"twenty":9.197529,"median":23.549925,"eighty":45.891374,"marketCap":5952947781},{"date":"2022-06-24","current":23.912825,"twenty":9.237499,"median":23.564333,"eighty":45.919924,"marketCap":7126858820},{"date":"2022-07-01","current":23.213305,"twenty":9.247736,"median":23.584442,"eighty":45.919924,"marketCap":6918377351},{"date":"2022-07-08","current":23.686826,"twenty":9.281845,"median":23.611294,"eighty":45.919924,"marketCap":7059503269},{"date":"2022-07-15","current":22.965782,"twenty":9.328108,"median":23.611294,"eighty":45.919924,"marketCap":6844606986},{"date":"2022-07-22","current":22.449214,"twenty":9.353834,"median":23.633017,"eighty":45.919924,"marketCap":6690651440},{"date":"2022-07-29","current":22.513785,"twenty":9.38718,"median":23.633017,"eighty":45.919924,"marketCap":6709895883},{"date":"2022-08-05","current":23.159496,"twenty":9.423477,"median":23.633017,"eighty":45.919924,"marketCap":6902340315},{"date":"2022-08-12","current":22.996839,"twenty":9.477679,"median":23.677084,"eighty":45.919924,"marketCap":6269283152},{"date":"2022-08-19","current":22.819758,"twenty":9.532448,"median":23.677084,"eighty":45.919924,"marketCap":6221008384},{"date":"2022-08-26","current":21.521169,"twenty":9.589879,"median":23.677084,"eighty":45.919924,"marketCap":5866993422},{"date":"2022-09-02","current":21.143397,"twenty":9.637235,"median":23.677084,"eighty":45.919924,"marketCap":5764007251},{"date":"2022-09-09","current":21.131592,"twenty":9.656291,"median":23.677084,"eighty":45.919924,"marketCap":5760788933},{"date":"2022-09-16","current":20.24619,"twenty":9.709392,"median":23.677084,"eighty":45.919924,"marketCap":5519415095},{"date":"2022-09-23","current":19.219124,"twenty":9.737158,"median":23.677084,"eighty":45.919924,"marketCap":5239421443},{"date":"2022-09-30","current":18.510802,"twenty":9.752596,"median":23.677084,"eighty":45.919924,"marketCap":5046322373},{"date":"2022-10-07","current":18.180252,"twenty":9.809283,"median":23.677084,"eighty":45.919924,"marketCap":4956209473},{"date":"2022-10-14","current":18.475386,"twenty":9.839263,"median":23.677084,"eighty":45.919924,"marketCap":5036667419},{"date":"2022-10-21","current":19.419815,"twenty":9.921087,"median":23.677084,"eighty":45.919924,"marketCap":5294132846},{"date":"2022-10-28","current":19.632311,"twenty":9.95111,"median":23.677084,"eighty":45.919924,"marketCap":5352062567},{"date":"2022-11-04","current":17.259423,"twenty":9.977849,"median":23.677084,"eighty":45.919924,"marketCap":5309360940},{"date":"2022-11-11","current":17.615936,"twenty":10.045835,"median":23.677084,"eighty":45.919924,"marketCap":5419031822},{"date":"2022-11-18","current":17.731278,"twenty":10.09551,"median":23.677084,"eighty":45.919924,"marketCap":5454513578},{"date":"2022-11-25","current":17.762735,"twenty":10.137764,"median":23.677084,"eighty":45.919924,"marketCap":5464190420},{"date":"2022-12-02","current":18.234591,"twenty":10.262522,"median":23.677084,"eighty":45.919924,"marketCap":5609343059},{"date":"2022-12-09","current":16.535911,"twenty":10.306552,"median":23.677084,"eighty":45.919924,"marketCap":5086793561},{"date":"2022-12-16","current":16.714168,"twenty":10.501618,"median":23.677084,"eighty":45.919924,"marketCap":5141629002},{"date":"2022-12-23","current":16.598825,"twenty":10.590509,"median":23.677084,"eighty":45.919924,"marketCap":5106147246},{"date":"2022-12-30","current":16.819025,"twenty":10.667114,"median":23.677084,"eighty":45.919924,"marketCap":5173885144},{"date":"2023-01-06","current":18.108763,"twenty":10.667114,"median":23.584442,"eighty":45.49168,"marketCap":5570635688},{"date":"2023-01-13","current":17.227966,"twenty":10.667114,"median":23.503875,"eighty":45.1654,"marketCap":5299684097},{"date":"2023-01-20","current":17.542536,"twenty":10.667114,"median":23.449537,"eighty":44.010071,"marketCap":5396452523},{"date":"2023-01-27","current":18.318476,"twenty":10.667114,"median":23.314972,"eighty":43.020435,"marketCap":5635147972},{"date":"2023-02-03","current":18.402362,"twenty":10.667114,"median":23.194326,"eighty":42.458135,"marketCap":5660952885},{"date":"2023-02-10","current":31.202932,"twenty":10.667114,"median":23.191781,"eighty":42.011762,"marketCap":5687732764},{"date":"2023-02-17","current":31.096255,"twenty":10.667114,"median":23.191781,"eighty":41.420955,"marketCap":5668287524},{"date":"2023-02-24","current":30.456195,"twenty":10.667114,"median":23.191781,"eighty":41.184268,"marketCap":5551616082},{"date":"2023-03-03","current":30.491754,"twenty":10.667114,"median":23.191781,"eighty":40.984929,"marketCap":5558097829},{"date":"2023-03-10","current":29.65612,"twenty":10.667114,"median":23.191781,"eighty":40.686627,"marketCap":5405776781},{"date":"2023-03-17","current":31.202932,"twenty":10.667114,"median":23.191781,"eighty":40.243946,"marketCap":5687732764},{"date":"2023-03-24","current":32.85642,"twenty":10.667114,"median":23.191781,"eighty":39.955417,"marketCap":5989133987},{"date":"2023-03-31","current":34.509909,"twenty":10.667928,"median":23.193053,"eighty":39.475483,"marketCap":6290535211},{"date":"2023-04-06","current":35.363322,"twenty":10.667928,"median":23.193053,"eighty":39.271956,"marketCap":6446097132},{"date":"2023-04-14","current":34.918836,"twenty":10.667114,"median":23.191781,"eighty":39.023166,"marketCap":6365075298},{"date":"2023-04-21","current":33.620936,"twenty":10.667114,"median":23.191781,"eighty":38.427704,"marketCap":6128491542},{"date":"2023-04-28","current":32.305257,"twenty":10.667114,"median":23.191781,"eighty":37.395181,"marketCap":5888666913},{"date":"2023-05-05","current":34.73643,"twenty":10.667114,"median":23.191781,"eighty":37.193084,"marketCap":6331825854},{"date":"2023-05-12","current":40.911234,"twenty":10.667114,"median":23.213305,"eighty":37.526354,"marketCap":6289570343},{"date":"2023-05-19","current":41.790934,"twenty":10.666299,"median":23.203815,"eighty":38.431783,"marketCap":6424812840},{"date":"2023-05-26","current":40.308235,"twenty":10.666299,"median":23.203815,"eighty":39.03948,"marketCap":6196867124},{"date":"2023-05-31","current":40.265872,"twenty":10.666299,"median":23.203815,"eighty":39.188346,"marketCap":6190354389},{"date":"2023-06-09","current":40.98604,"twenty":10.659474,"median":23.193053,"eighty":39.394311,"marketCap":6301070880},{"date":"2023-06-16","current":40.456505,"twenty":10.636307,"median":23.23296,"eighty":39.77769,"marketCap":6219661695},{"date":"2023-06-22","current":40.265872,"twenty":10.614439,"median":23.277876,"eighty":40.236218,"marketCap":6190354389},{"date":"2023-06-26","current":42.066293,"twenty":10.603505,"median":23.311527,"eighty":40.265872,"marketCap":6467145616},{"date":"2023-07-07","current":40.943677,"twenty":10.600095,"median":23.213305,"eighty":40.520035,"marketCap":6294558145},{"date":"2023-07-14","current":40.98604,"twenty":10.600095,"median":23.213305,"eighty":40.545455,"marketCap":6301070880},{"date":"2023-07-21","current":42.087474,"twenty":10.600095,"median":23.213305,"eighty":40.680159,"marketCap":6470401984},{"date":"2023-07-28","current":41.515576,"twenty":10.600095,"median":23.213305,"eighty":40.924511,"marketCap":6382480064},{"date":"2023-08-04","current":40.24272,"twenty":10.600095,"median":23.354574,"eighty":40.932036,"marketCap":6609585096},{"date":"2023-08-11","current":40.998725,"twenty":10.600095,"median":23.481924,"eighty":40.941559,"marketCap":6733753602},{"date":"2023-08-18","current":40.707954,"twenty":10.600095,"median":23.579987,"eighty":40.983764,"marketCap":6685996485},{"date":"2023-08-25","current":42.161809,"twenty":10.600095,"median":23.703849,"eighty":41.024602,"marketCap":6924782073},{"date":"2023-09-01","current":43.402433,"twenty":10.600095,"median":23.784876,"eighty":41.205168,"marketCap":7128545776},{"date":"2023-09-08","current":42.685197,"twenty":10.600095,"median":23.881479,"eighty":41.417849,"marketCap":7010744885},{"date":"2023-09-15","current":43.169816,"twenty":10.600095,"median":23.959006,"eighty":41.704282,"marketCap":7090340081},{"date":"2023-09-22","current":41.832269,"twenty":10.600095,"median":24.063445,"eighty":41.742049,"marketCap":6870657340},{"date":"2023-09-29","current":43.402433,"twenty":10.600095,"median":24.159779,"eighty":41.859163,"marketCap":7128545776},{"date":"2023-10-06","current":42.917814,"twenty":10.600095,"median":24.411169,"eighty":41.925256,"marketCap":7048950579},{"date":"2023-10-13","current":41.173188,"twenty":10.600095,"median":24.472259,"eighty":41.970666,"marketCap":6762407873},{"date":"2023-10-20","current":40.378413,"twenty":10.600095,"median":24.601456,"eighty":42.032402,"marketCap":6631871751},{"date":"2023-10-27","current":40.688569,"twenty":10.590509,"median":24.763289,"eighty":42.053584,"marketCap":6682812677},{"date":"2023-11-03","current":67.987802,"twenty":10.590509,"median":24.82708,"eighty":42.104419,"marketCap":6259908894},{"date":"2023-11-10","current":70.993721,"twenty":10.590509,"median":24.916894,"eighty":42.169563,"marketCap":6536675855},{"date":"2023-11-17","current":70.858623,"twenty":10.590509,"median":25.114925,"eighty":42.251018,"marketCap":6524236890},{"date":"2023-11-24","current":73.222829,"twenty":10.590509,"median":25.234082,"eighty":42.431195,"marketCap":6741918769},{"date":"2023-12-01","current":73.661896,"twenty":10.590509,"median":25.380185,"eighty":42.822269,"marketCap":6782345404},{"date":"2023-12-08","current":74.269835,"twenty":10.594875,"median":25.475549,"eighty":42.99923,"marketCap":6838320744},{"date":"2023-12-15","current":78.728051,"twenty":10.594875,"median":25.683605,"eighty":43.169816,"marketCap":7248806574},{"date":"2023-12-22","current":79.302215,"twenty":10.594875,"median":25.809174,"eighty":43.432834,"marketCap":7301672173},{"date":"2023-12-29","current":81.497549,"twenty":10.590509,"median":25.871438,"eighty":43.801759,"marketCap":7503805346},{"date":"2024-01-05","current":79.741282,"twenty":10.586142,"median":26.026128,"eighty":45.173557,"marketCap":7342098807},{"date":"2024-01-12","current":75.688358,"twenty":10.586142,"median":26.123266,"eighty":45.499837,"marketCap":6968929872},{"date":"2024-01-19","current":75.215517,"twenty":10.581776,"median":26.310309,"eighty":46.429737,"marketCap":6925393496},{"date":"2024-01-26","current":74.607578,"twenty":10.586142,"median":26.757641,"eighty":47.070063,"marketCap":6869418156},{"date":"2024-02-02","current":73.45925,"twenty":10.586142,"median":26.8819,"eighty":48.970648,"marketCap":6763686957},{"date":"2024-02-09","current":29.434352,"twenty":10.586142,"median":27.133306,"eighty":50.736642,"marketCap":6115428204},{"date":"2024-02-16","current":30.047264,"twenty":10.666299,"median":27.737543,"eighty":50.736642,"marketCap":6242769792},{"date":"2024-02-23","current":30.222382,"twenty":10.755729,"median":28.081886,"eighty":50.736642,"marketCap":6279153103},{"date":"2024-03-01","current":31.958965,"twenty":12.580654,"median":28.465994,"eighty":50.389968,"marketCap":6639954272},{"date":"2024-03-08","current":32.236234,"twenty":14.477572,"median":28.687196,"eighty":50.389968,"marketCap":6697561181},{"date":"2024-03-15","current":32.995077,"twenty":15.693391,"median":29.087177,"eighty":50.389968,"marketCap":6855222195},{"date":"2024-03-22","current":34.906778,"twenty":16.21505,"median":29.378454,"eighty":50.389968,"marketCap":7252406675},{"date":"2024-03-28","current":34.819219,"twenty":16.431775,"median":29.448945,"eighty":50.389968,"marketCap":7234215019},{"date":"2024-04-05","current":34.279273,"twenty":16.579951,"median":29.605173,"eighty":50.736642,"marketCap":7122033143},{"date":"2024-04-12","current":33.05345,"twenty":16.813772,"median":29.772048,"eighty":50.736642,"marketCap":6867349966},{"date":"2024-04-19","current":31.911299,"twenty":16.916749,"median":30.058488,"eighty":50.736642,"marketCap":6630050987},{"date":"2024-04-26","current":33.386966,"twenty":17.091652,"median":30.249439,"eighty":50.389968,"marketCap":6936642941},{"date":"2024-05-03","current":31.422916,"twenty":17.176551,"median":30.506341,"eighty":50.389968,"marketCap":6443394612},{"date":"2024-05-10","current":30.911512,"twenty":17.328629,"median":30.882901,"eighty":50.389968,"marketCap":6338529239},{"date":"2024-05-17","current":30.158612,"twenty":17.488992,"median":30.882901,"eighty":50.389968,"marketCap":6184144105},{"date":"2024-05-24","current":28.993748,"twenty":17.580284,"median":30.882901,"eighty":50.389968,"marketCap":5945284088},{"date":"2024-05-31","current":29.519358,"twenty":17.615936,"median":30.882901,"eighty":50.389968,"marketCap":6053062389},{"date":"2024-06-07","current":31.50815,"twenty":17.668364,"median":30.926871,"eighty":50.389968,"marketCap":6460872174},{"date":"2024-06-14","current":31.195625,"twenty":17.731278,"median":31.024392,"eighty":50.736642,"marketCap":6396787779},{"date":"2024-06-21","current":30.868895,"twenty":17.766317,"median":31.025137,"eighty":51.083315,"marketCap":6329790457},{"date":"2024-06-28","current":32.005348,"twenty":17.852912,"median":31.063965,"eighty":53.63882,"marketCap":6562824621},{"date":"2024-07-05","current":31.195625,"twenty":17.982935,"median":31.110391,"eighty":53.63882,"marketCap":6396787779},{"date":"2024-07-12","current":32.033759,"twenty":18.146511,"median":31.178387,"eighty":53.63882,"marketCap":6568650475},{"date":"2024-07-15","current":31.820674,"twenty":18.176822,"median":31.195625,"eighty":53.63882,"marketCap":6524956569},{"date":"2024-08-02","current":34.406104,"twenty":18.456098,"median":31.288944,"eighty":57.789598,"marketCap":7055109290},{"date":"2024-08-09","current":22.14419,"twenty":18.510802,"median":31.323476,"eighty":57.789598,"marketCap":7750289368},{"date":"2024-08-16","current":21.44327,"twenty":18.768662,"median":31.323476,"eighty":57.789598,"marketCap":7504972884},{"date":"2024-08-23","current":21.011307,"twenty":18.973137,"median":31.323476,"eighty":57.789598,"marketCap":7353789470},{"date":"2024-08-30","current":21.206913,"twenty":19.112302,"median":31.323476,"eighty":57.789598,"marketCap":7422249884},{"date":"2024-09-06","current":20.840152,"twenty":19.183708,"median":31.323476,"eighty":57.789598,"marketCap":7293886608},{"date":"2024-09-13","current":21.44327,"twenty":19.289956,"median":31.323476,"eighty":57.789598,"marketCap":7504972884},{"date":"2024-09-20","current":21.867082,"twenty":19.478842,"median":31.323476,"eighty":57.789598,"marketCap":7653303781},{"date":"2024-09-27","current":21.386218,"twenty":19.575801,"median":31.323476,"eighty":57.789598,"marketCap":7485005264},{"date":"2024-10-04","current":21.386218,"twenty":19.877132,"median":31.323476,"eighty":57.789598,"marketCap":7485005264},{"date":"2024-10-11","current":20.954256,"twenty":20.21075,"median":31.323476,"eighty":57.789598,"marketCap":7333821849},{"date":"2024-10-18","current":23.684585,"twenty":20.318368,"median":31.323476,"eighty":57.789598,"marketCap":8289415128},{"date":"2024-10-25","current":22.910312,"twenty":20.693448,"median":31.323476,"eighty":57.789598,"marketCap":8018425989},{"date":"2024-10-31","current":19.840881,"twenty":20.791251,"median":31.323476,"eighty":57.789598,"marketCap":9264183408},{"date":"2024-11-08","current":21.895917,"twenty":20.951195,"median":31.330579,"eighty":57.923603,"marketCap":10223728916},{"date":"2024-11-15","current":21.437203,"twenty":20.974348,"median":31.330579,"eighty":57.923603,"marketCap":10009544651},{"date":"2024-11-22","current":21.302647,"twenty":21.045396,"median":31.330579,"eighty":57.923603,"marketCap":9946717266},{"date":"2024-11-29","current":22.299584,"twenty":21.095503,"median":31.330579,"eighty":57.923603,"marketCap":10412211069},{"date":"2024-12-06","current":22.042705,"twenty":21.156382,"median":31.330579,"eighty":57.923603,"marketCap":10292267880},{"date":"2024-12-13","current":21.516713,"twenty":21.234624,"median":31.330579,"eighty":57.923603,"marketCap":10046669923},{"date":"2024-12-20","current":20.599287,"twenty":21.262689,"median":31.330579,"eighty":57.923603,"marketCap":9618301393},{"date":"2024-12-27","current":20.813353,"twenty":21.262689,"median":31.330579,"eighty":57.923603,"marketCap":9718254050},{"date":"2025-01-03","current":20.758307,"twenty":21.262689,"median":31.330579,"eighty":57.923603,"marketCap":9692551938},{"date":"2025-01-10","current":21.100813,"twenty":21.272083,"median":31.337682,"eighty":58.057608,"marketCap":9852476190},{"date":"2025-01-17","current":22.35463,"twenty":21.382958,"median":31.337682,"eighty":58.057608,"marketCap":10437913181},{"date":"2025-01-24","current":20.874515,"twenty":21.386218,"median":31.337682,"eighty":58.057608,"marketCap":9746811952},{"date":"2025-01-31","current":20.140573,"twenty":21.386218,"median":31.337682,"eighty":58.057608,"marketCap":9404117128},{"date":"2025-02-07","current":20.593171,"twenty":21.386218,"median":31.337682,"eighty":58.057608,"marketCap":9615445603},{"date":"2025-02-14","current":18.518554,"twenty":21.386218,"median":31.337682,"eighty":58.057608,"marketCap":9653111210},{"date":"2025-02-21","current":18.840709,"twenty":21.386218,"median":31.337682,"eighty":58.057608,"marketCap":9821040080},{"date":"2025-02-28","current":20.215238,"twenty":21.386218,"median":31.337682,"eighty":58.057608,"marketCap":10537536592},{"date":"2025-03-07","current":20.515916,"twenty":21.399258,"median":31.337682,"eighty":58.191612,"marketCap":10694270204},{"date":"2025-03-14","current":19.758852,"twenty":21.399258,"median":31.337682,"eighty":58.191612,"marketCap":10299637360},{"date":"2025-03-21","current":19.962883,"twenty":21.399258,"median":31.337682,"eighty":58.191612,"marketCap":10405992311},{"date":"2025-03-28","current":19.780329,"twenty":21.399258,"median":31.337682,"eighty":58.191612,"marketCap":10310832618},{"date":"2025-04-04","current":19.694421,"twenty":21.399258,"median":31.337682,"eighty":58.191612,"marketCap":10266051586}],"updateTime":1743887307123}}}